| Previous Close | 3.2800 |
| Open | 3.0700 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's Range | 3.0000 - 3.0800 |
| 52 Week Range | 1.5200 - 4.1000 |
| Volume | 3,273 |
| Avg. Volume | 8,833 |
| Market Cap | 5.706M |
| Beta (3Y Monthly) | 0.91 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -15.2450 |
| Earnings Date | Aug 14, 2019 - Aug 24, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 1.57 |
SOUTH EASTON, MA / ACCESSWIRE / July 18, 2019 / Pressure BioSciences, Inc. (PBIO) (“PBI” and the “Company”), a leader in the development and sale of innovative, broadly enabling, pressure-based instruments and related consumables for the worldwide life sciences and other industries, today announced that its flagship Barocycler 2320EXTREME instrument was prominently featured at a three-day, internationally-attended scientific conference held at the elite Westlake University (“Westlake”) in Hangzhou, China. One of the primary conference organizers was Professor Tiannan Guo, MD., PhD, a well-known protein research scientist. In 2017, Professor Guo’s Westlake laboratory was named a PBI Center of Excellence.
SOUTH EASTON, MA / ACCESSWIRE / June 27, 2019 / Pressure BioSciences, Inc. (PBIO) ("PBI" or the "Company"), a leader in the development and sale of broadly enabling, pressure-based instruments, consumables, and platform technology solutions to the worldwide life sciences industry, today announced the launch of its BaroShear™ K45 system based on the Company's proprietary Ultra Shear Technology™ (UST™) platform. The BaroShear K45 system is a unique and powerful next generation nanoemulsification system designed to fix one of the most critical problems facing CBD manufacturers today: the extremely poor water solubility of CBD oil. Because of these solubility issues, many CBD products on the market today contain an inefficient over-abundance of CBD and/or undesirable chemicals to try and improve its solubility in water.
Proprietary, Custom Built UST-Based Instrument Delivered to Collaborators at The Ohio State University; OSU Scientists to Study Pressure and Shear Effects on Pathogen Inactivation, Stability, and Quality ...
HUB Platform Plays Critical Role in Innovative Research Studies Designed to Increase Understanding of and Develop Methods for the Prevention of Serious Food-Borne Diseases Caused by E. coli and Listeria ...
SOUTH EASTON, MA / ACCESSWIRE / June 12, 2019 / Pressure BioSciences, Inc. (PBIO) ("PBI" or the "Company"), a leader in the development and sale of broadly enabling, pressure-base instruments, consumables, and platform technology solutions to the worldwide life sciences industry, today announced that the Company's patented pressure cycling technology ("PCT") platform was prominently featured in 15 independent presentations at the annual conference of the American Society for Mass Spectrometry ("ASMS"), held from June 1-6, 2019 in Atlanta, GA. The presentations spanned wide ranging applications for PBI's unique PCT platform in scientific studies, particularly their essential use in advancing knowledge and understanding in such areas as cancer research, protein function, molecular biology, and biomarker discovery.
Q1 Revenue from Newly Created BioPharma and UST Contract Services Significantly Exceeds Services Revenue for All Quarters of 2018 Combined Investor Conference Call Scheduled for Thursday, May 16, 2019 ...
Conference Call Scheduled for Thursday, May 16 th at 4:30pm ET SOUTH EASTON, MA / ACCESSWIRE / May 15, 2019 / Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" and the "Company") today ...
SOUTH EASTON, MA / ACCESSWIRE / May 1, 2019 / Pressure BioSciences, Inc. (PBIO) ("PBI" and the "Company"), a leader in the development and sale of innovative, broadly enabling, pressure-based instruments and related consumables for the worldwide life sciences industry, today announced that Mr. Richard T. Schumacher, the Founder of the Company, notified the Company's Board of Directors on April 25, 2019 that he plans to step down as President and CEO effective September 9, 2019. Mr. Schumacher has been working with the Company's Board of Directors on leadership succession planning for many months, including the selection of Bradford A. Young, PhD, MBA, as SVP & Chief Commercial Officer ("CCO") for the Company in November 2018.
Q4 2018 Total Revenue Increases 37% over Q4 2017, Setting New Record Quarterly High; FY 2018 Total Revenue Increases 10% over FY 2017, Setting New Record Annual High; Initial Revenue Reported from New ...
Conference Call Scheduled for Thursday, April 25 th at 4:30pm ET SOUTH EASTON, MA / ACCESSWIRE / April 24, 2019 / Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" and the "Company") ...
PHOENIX, AZ / ACCESSWIRE / April 8, 2019 / Uptick Newswire recently welcomed Dr. Bradford A. Young, Senior Vice President and Chief Commercial Officer of Pressure BioSciences, Inc. (PBIO) ("PBI" or "the Company") to The Stock Day Podcast. The interview was hosted by Mr. Everett Jolly. To begin the interview, Mr. Jolly asked Dr. Young what makes the Company's Ultra Shear Technology (UST) platform one of the most effective methods known when it comes to mixing CBD oil and water.
New Video Demonstrates Revolution in Soft Drinks, Sports Drinks, and Beer with Vanishing Water-Soluble CBD Oil for Enhanced Quality and Absorption SOUTH EASTON, MA / ACCESSWIRE / April 2, 2019 / Pressure ...
The Company's entry into protein therapeutics and nanoemulsion solutions using breakthrough technologies coupled with its core instruments enable it to provide transformative solutions to the life sciences industry Easton, Pennsylvania--(Newsfile Corp. - March 29, 2019) - Small Caps Daily recently published a full report on Pressure BioSciences, Inc. (OTCQB: PBIO), after the Company's latest surge in press coverage piqued the publication's interest. The media interest is warranted, as it surrounds the commercial launch of ...
SOUTH EASTON, MA / ACCESSWIRE / March 27, 2019 / Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" and the "Company"), a leader in the development and sale of innovative, broadly enabling, pressure-based instruments and related consumables for the worldwide life sciences and other industries, today announced the establishment of a Center of Excellence ("CoE") at Dr. Christine Vogel's laboratory at New York University ("NYU")'s Center for Genomics and Systems Biology (the "GSB Center"). As a Center of Excellence, the Vogel Lab will have free use of the Company's primary instrument system, the Barocycler 2320EXTREME (the "2320EXT") until the end of 2020.
PHOENIX, AZ / ACCESSWIRE / March 6, 2019 / Uptick Newswire Stock Day Podcast welcomed Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" or the "Company"), a leader in the development and sale of innovative, broadly enabling, pressure-based solutions for the worldwide life sciences industry. The Company's President and CEO, Mr. Richard T. Schumacher, joined Stock Day host Mr. Everett Jolly to discuss the Company's progress in developing its unique and proprietary Ultra Shear Technology (UST) platform, and the use of this platform to process Hemp CBD Oil into a water-soluble ''nanoemulsion''.
SOUTH EASTON, MA / ACCESSWIRE / March 4, 2019 / Pressure BioSciences, Inc. (PBIO) ("PBI" and the "Company"), a leader in the development and sale of pressure-based instruments and platform technologies to the life sciences and other industries worldwide, today announced a collaboration with The Steinbeis Centre for Biopolymer Analysis & Biomedical Mass Spectrometry ("The Steinbeis Centre"), a world-renown German research organization. The collaboration is combining the unique capabilities of PBI's patented pressure cycling technology ("PCT") for sample preparation, protein characterization, and biotherapeutics quality control with the Steinbeis Centre's innovative PROTEX-MS instrument for elucidating structural details of antibody interactions to create an instrument system to accelerate the development of new protein therapeutics and improve existing drug treatments.
SOUTH EASTON, MA / ACCESSWIRE / February 21, 2019 / Pressure BioSciences, Inc. (PBIO) ("PBI" and the "Company") is a leader in the development and sale of broadly enabling, pressure-based instruments, consumables, and platform technology solutions to the life sciences and other industries. The Company today announced that analytical testing on hemp-derived CBD oil processed via PBI's Ultra Shear Technology™ (UST™) platform has confirmed that UST processing uniquely achieves the challenging criteria for creating highly-effective "nanoemulsions" of CBD oil in water, without loss or modification of CBD throughout the entire UST process ( 99% recovery).
New Video Demonstrates PBI's Ultra Shear Technology and Potential Impact in CBD, Nutraceuticals, Foods, Cosmetics, and Other Oil-Based Markets SOUTH EASTON, MA / ACCESSWIRE / February 13, 2019 / Pressure ...
Uptick Newswire Stock Day Podcast welcomed Pressure BioSciences, Inc. (OTCQB:PBIO) ("PBI" or the "Company"), a leader in the development and sale of innovative, broadly enabling, pressure-based solutions for the worldwide life sciences industry, to update Stock Day’s listeners on PBI’s three recent press releases. The Company’s President and CEO, Mr. Richard T. Schumacher, joined Stock Day’s Mr. Everett Jolly to discuss their recent successes. Mr. Jolly began the interview by asking Mr. Schumacher to explain to new listeners the Company’s products and how the Company generates revenue.
Primary Goal is to Optimize PBI's UST Platform for the Development and Manufacture of the Next Generation of New and Improved Nutraceutical and Other Large Market Emulsion-based Products, Such as Cosmetics and Pharmaceuticals. SOUTH EASTON, MA / ACCESSWIRE / January 30, 2019 / Pressure BioSciences, Inc. (PBIO) and NutraFuels, Inc. (NTFU) (together, the ''Companies'') today announced a collaboration to advance the development of a new generation of health and wellness nutraceutical products based on processing by PBI's proprietary Ultra Shear Technology (UST™) platform.
Coconut Creek, Florida--(Newsfile Corp. - January 30, 2019) - NutraFuels, Inc. (OTCQB: NTFU) (NTFU) and Pressure BioSciences, Inc. (OTCQB: PBIO) (PBI) (together, the "Companies") today announced a collaboration to advance the development of a new generation of health and wellness nutraceutical products based on processing by PBI's proprietary Ultra Shear Technology (UST™) platform. The Companies believe that nanoemulsions prepared by the UST Platform will have improved quality and effectiveness compared to current emulsions, which ...
SOUTH EASTON, MA / ACCESSWIRE / January 24, 2019 / Pressure BioSciences, Inc. (PBIO) ("PBI" or the "Company"), a leader in the development and sale of broadly enabling, pressure-based instruments, consumables, and platform technology solutions to the life sciences and other industries, today announced that more than 20 scientific papers citing the advantages of the Company's pressure cycling technology ("PCT") platform were published by independent researchers worldwide in 2018. The publications, authored by scientists from academia, government, and industry, described a wide range of enabling applications for PBI's patented PCT Platform in cancer research, biomarker discovery, and food safety, as well as in proteomic and molecular biology studies.
SOUTH EASTON, MA / ACCESSWIRE / January 7, 2019 / Pressure BioSciences, Inc. (PBIO) ("PBI" and the "Company"), a leader in the development and sale of enabling high pressure-based instruments, consumables, and related services for the worldwide life sciences industry, today announced the commercial launch of its Biopharmaceuticals Contract Services Business. The launch of this new business has been eagerly anticipated following the Company's acquisition of the assets of BaroFold, Inc. in December 2017, including patents, equipment, and other intellectual property relating to Barofold's unique, high pressure-based protein disaggregation and refolding platform. PBI expects that the unique Barofold technology platform will substantially improve the quality and costs of manufacturing protein therapeutics, by helping to resolve protein aggregation, improving solubility, and refolding complex misfolded protein therapeutic molecules into their desired, therapeutically-optimized conformations for improved drug efficacy and lower immunogenicity.
SOUTH EASTON, MA / ACCESSWIRE / December 18, 2018 / Pressure BioSciences, Inc. (PBIO) ("PBI" or the "Company") is a leader in the development and sale of broadly enabling, pressure-based instruments, consumables, and platform technology solutions to the worldwide life sciences and other industries. The Company today announced that a team of scientists from the Centre for the Proteome of Human Cancer ("ProCan”) has published a recommended, streamlined, proteomic sample preparation protocol built around PBI's Barocycler instrument system, designed to help optimize the identification and use of novel cancer biomarkers for the improved diagnosis and treatment of cancers.